Four years and $145M+ lat­er, No­vo Nordisk hands back the rights to hor­mone growth de­fi­cien­cy test

Af­ter chang­ing hands a cou­ple of times, Aeter­na Zen­taris’ adult growth hor­mone de­fi­cien­cy (AGHD) test Macrilen is re­turn­ing to its orig­i­nal de­vel­op­er as No­vo Nordisk for­feits the rights.

Aeter­na an­nounced on Mon­day that the Dan­ish phar­ma is re­turn­ing the US and Cana­da rights, just four years af­ter plunk­ing down $145 mil­lion plus tiered roy­al­ties and an eq­ui­ty in­vest­ment worth more than $36 mil­lion to se­cure the oral ghre­lin ag­o­nist.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER